Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01594749
First received: April 24, 2012
Last updated: November 17, 2014
Last verified: November 2014
  Purpose

This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).


Condition Intervention Phase
Chemotherapy-Induced Nausea and Vomiting (CINV)
Drug: Fosaprepitant dimeglumine
Drug: Fosaprepitant Placebo
Drug: Dexamethasone
Drug: Ondansetron
Drug: Dexamethasone Placebo
Drug: Ondansetron Placebo
Drug: Rescue Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Number of participants with Complete Response from 25 to 120 hours after initiation of MEC. [ Time Frame: 25 to 120 hours ] [ Designated as safety issue: No ]
  • Number of participants with infusion-site thrombophlebitis [ Time Frame: Day 1 ] [ Designated as safety issue: Yes ]
  • Number of participants with severe infusion-site reactions, including site pain, or site redness (erythema) or site hardness (induration) [ Time Frame: Day 1 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of participants with Complete Response from 0 to 120 hours after initiation of MEC [ Time Frame: 0 to 120 hours ] [ Designated as safety issue: No ]
  • Number of participants with Complete Response from 0 to 24 hours after initiation of MEC [ Time Frame: 0 to 24 hours ] [ Designated as safety issue: No ]
  • Number of participants with No Vomiting from 0 to 120 hours after initiation of MEC [ Time Frame: 0 to 120 hours ] [ Designated as safety issue: No ]

Enrollment: 1015
Study Start Date: September 2012
Study Completion Date: November 2014
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fosaprepitant IV

Fosaprepitant dimeglumine: Single 150 mg dose intravenously, approximately (~) 30 minutes prior to chemotherapy on Day 1

Dexamethasone 12 mg: orally (po) on Day 1, ~30 minutes prior to chemotherapy

Ondansetron 16 mg: 8 mg po, ~30-60 minutes prior to chemotherapy, followed by 8 mg po, 8 hours after first dose for a total dose of 16 mg on Day 1.

Dexamethasone Placebo: po, ~30 minutes prior to chemotherapy on Day 1

Ondansetron Placebo: po every 12 hours, on Days 2 and 3

Rescue Therapy: For established cases of nausea or vomiting, medications may be prescribed at the investigator's discretion from the following list of permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.

Drug: Fosaprepitant dimeglumine
Other Names:
  • EMEND for Injection
  • MK-0517
Drug: Dexamethasone
Other Name: Decadron
Drug: Ondansetron
Other Name: Zofran
Drug: Dexamethasone Placebo Drug: Ondansetron Placebo Drug: Rescue Therapy
Active Comparator: Control Therapy

Fosaprepitant Placebo: Fosaprepitant placebo in the form of 150 mL of 0.9% normal saline intravenously, ~30 minutes hour prior to chemotherapy on Day 1

Dexamethasone 20 mg: po, ~30 minutes prior to chemotherapy on Day 1

Ondansetron 16 mg: Day 1 - 8 mg orally, ~30-60 minutes prior to chemotherapy; followed by 8 mg orally, 8 hours after the first dose for a total daily dose of 16 mg. Days 2-3 - 8 mg orally every 12 hours.

Rescue Therapy: For established cases of nausea or vomiting, medications may be prescribed at the investigator's discretion from the following list of permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.

Drug: Fosaprepitant Placebo Drug: Dexamethasone
Other Name: Decadron
Drug: Ondansetron
Other Name: Zofran
Drug: Rescue Therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a histologically or cytologically confirmed malignant disease
  • Is naive to moderately and highly emetogenic chemotherapy
  • Is scheduled to receive a single IV dose of one or more MEC agents on Day 1, except for the combination of anthracycline and cyclophosphamide (AC MEC)
  • Has a predicted life expectancy of at least 4 months, and a Karnofsky score of at least 60 indicating that the subject requires occasional assistance, but is able to care for most of his/her needs.
  • Female of childbearing potential demonstrates a negative urine pregnancy test, and agrees to remain abstinent or use two acceptable forms of birth control for at least 14 days prior to study, throughout the study, and at least 1 month following last dose of study medication

Exclusion Criteria:

  • Has vomited in the 24 hours prior to treatment Day 1
  • Has symptomatic primary or metastatic symptomatic central nervous system (CNS) malignancy causing nausea and/or vomiting
  • Is scheduled to receive chemotherapy agent classified as highly emetogenic
  • Has received or will receive total body irradiation (TBI), or radiation therapy to the abdomen, pelvis, head and neck in the week prior to Treatment Days 1 through Day 6 of the Treatment Period
  • Has illness or history of illness which might confound study results or pose unwarranted risk
  • Known history of QT prolongation
  • Uses illicit drugs or abuses alcohol
  • Mentally incapacitated or has a significant emotional or psychiatric disorder
  • History of hypersensitivity to aprepitant, ondansetron or dexamethasone
  • Pregnant or breast-feeding
  • Has participated in a study with aprepitant or taken a non-approved (investigational) drug within the last 4 weeks
  • Has concurrent condition, such as systemic fungal infection or uncontrolled diabetes, that precludes administration of dexamethasone
  • Takes other excluded medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01594749

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Director Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01594749     History of Changes
Other Study ID Numbers: 0517-031
Study First Received: April 24, 2012
Last Updated: November 17, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Merck Sharp & Dohme Corp.:
NK-1 Receptor Antagonist, CINV, Emesis, MEC

Additional relevant MeSH terms:
Nausea
Vomiting
Signs and Symptoms
Signs and Symptoms, Digestive
Aprepitant
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Fosaprepitant
Ondansetron
Anti-Anxiety Agents
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antipruritics
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dermatologic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents

ClinicalTrials.gov processed this record on November 19, 2014